Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hepatology

Type I vs. Type II: Understanding Your Child's Subtype

At a Glance

Crigler-Najjar Syndrome (CNS) is divided into Type I and Type II based on the liver's UGT1A1 enzyme activity. Type I has no enzyme activity and requires aggressive phototherapy or a liver transplant. Type II has partial activity and often responds to daily phenobarbital medication.

Determining whether your child has Crigler-Najjar Syndrome (CNS) Type I or Type II is the most critical step in their care journey. While both types involve the same gene, the “why” and “how” of the enzyme deficiency differ significantly, leading to two very different paths for treatment and daily life [1][2].

The Two Faces of CNS: Type I vs. Type II

The primary difference between the two types is the amount of functional UGT1A1 enzyme your child’s liver can produce.

  • Type I (CNS-I): In this severe form, the liver has zero or near-zero enzyme activity [3][4]. The body has no way to process bilirubin on its own. This typically results from nonsense mutations—genetic “stop” signs that tell the body to stop building the enzyme before it is finished [5].
  • Type II (CNS-II): This is a milder form where the liver has partial enzyme activity [6][3]. The enzyme is “broken” but still functions at a very low level. This is often caused by missense mutations, where a single “typo” in the genetic code results in an enzyme that works poorly but is not entirely absent [7][8].

The Phenobarbital Challenge

One of the most important diagnostic tools is the phenobarbital challenge [6]. Phenobarbital is a medication that can “induce” or jumpstart the UGT1A1 enzyme, making it work harder.

  • In Type II: After taking phenobarbital for two to three weeks, bilirubin levels typically drop by 60% to 70% [6][9]. This dramatic response confirms that there is some working enzyme present to be jumpstarted [10].
  • In Type I: There is usually no significant response to phenobarbital [6]. Because the enzyme is entirely absent or non-functional, no amount of medication can force it to work [11][12].

Understanding the Lab Values

Doctors use specific blood tests to monitor CNS. You will often see several types of bilirubin listed on a lab report. In CNS, the “Total” and “Unconjugated” (also called Indirect) levels will be high, while the “Conjugated” (Direct) level remains very low because the liver cannot complete the transformation [3][13].

Lab Value Type I (CNS-I) Type II (CNS-II)
Total Bilirubin Often > 20 mg/dL (342 µmol/L) [14][15] Typically 6–20 mg/dL (103–342 µmol/L) [14][7]
Enzyme Activity None (0%) [3][4] Partial (< 10% of normal) [3][4]
Phenobarbital Response No change [6] Significant drop (> 25-30%) [6][9]
Risk of Kernicterus Very High without treatment [1][16] Present, but generally lower [17][18]

Your Diagnosis “Completeness Checklist”

To ensure your child has a clear care path, their medical records should ideally include the following:

  • [ ] Fractionated Bilirubin Panel: This breaks down the Total, Direct (Conjugated), and Indirect (Unconjugated) levels. In CNS, the high levels must be almost entirely Unconjugated [19].
  • [ ] Full UGT1A1 Genetic Sequencing: This identifies the specific mutations. Knowing if the mutations are “nonsense,” “missense,” or “frameshift” helps predict how the disease will behave [3][5].
  • [ ] Phenobarbital Trial Results: Documentation of bilirubin levels before and after a 2–3 week trial of phenobarbital [6].
  • [ ] Promoter Analysis: A check for the A(TA)nTAA polymorphism, which can sometimes make bilirubin levels even higher in children who already have CNS mutations [3][20].

Why the Subtype Matters

Identifying the subtype is not just about a label; it dictates your child’s daily life.

  • Type I requires aggressive, lifelong phototherapy (often 10–12 hours a day) and may ultimately require a liver transplant to prevent brain damage [1][21].
  • Type II may be managed primarily with daily phenobarbital and careful monitoring, though phototherapy may still be needed during illnesses or periods of high stress [2][8].

Knowing exactly which type your child has allows your medical team to build a safety net that protects their brain and ensures they reach their full potential.

Common questions in this guide

What is the main difference between Crigler-Najjar Type I and Type II?
The primary difference is the amount of functional UGT1A1 enzyme your child's liver can produce. Type I is a severe form with zero enzyme activity, while Type II is a milder form where the liver has partial enzyme activity.
What is the phenobarbital challenge?
The phenobarbital challenge is a diagnostic test where a child takes the medication phenobarbital for two to three weeks. If bilirubin levels drop significantly, it indicates Type II. If there is no response, it indicates Type I.
How do the genetic mutations differ between Type I and Type II?
Type I is typically caused by nonsense mutations, which act as genetic stop signs that halt enzyme production. Type II is usually caused by missense mutations, which act like genetic typos that create a poorly functioning enzyme.
What lab results indicate Crigler-Najjar Syndrome?
Blood tests will show very high Total and Unconjugated (Indirect) bilirubin levels, while Conjugated (Direct) bilirubin levels remain very low. This pattern occurs because the liver cannot complete the transformation of bilirubin.
How does the subtype change my child's treatment plan?
Type I requires aggressive, lifelong phototherapy and may eventually require a liver transplant to prevent brain damage. Type II is often managed with daily phenobarbital medication and careful monitoring, though phototherapy may be needed during illness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the genetic report, does my child have nonsense mutations or missense mutations, and what does this tell us about their subtype?
  2. 2.What was the exact percentage drop in my child's bilirubin during the phenobarbital challenge?
  3. 3.Is my child's current bilirubin level consistently within the safe range, and what is the specific threshold where we should seek emergency care?
  4. 4.Does my child have any promoter polymorphisms, like the A(TA)7TAA variant, that might be affecting their bilirubin levels?
  5. 5.How does this subtype diagnosis change our long-term plan regarding phototherapy versus potential liver transplantation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Disease burden of Crigler-Najjar syndrome: Systematic review and future perspectives.

    Dhawan A, Lawlor MW, Mazariegos GV, et al.

    Journal of gastroenterology and hepatology 2020; (35(4)):530-543 doi:10.1111/jgh.14853.

    PMID: 31495946
  2. 2

    Crigler Najjar Syndrome Type 2 (CNS Type 2): An Unwonted Cause of Jaundice in Adults.

    Kumar P, Sasmal G, Gupta S, et al.

    Journal of clinical and diagnostic research : JCDR 2017; (11(7)):OD05-OD06 doi:10.7860/JCDR/2017/28195.10221.

    PMID: 28892962
  3. 3

    Spectrum of UGT1A1 variants in Pakistani children affected with inherited unconjugated hyperbilirubinemias.

    Zubaida B, Cheema HA, Hashmi MA, Naeem M

    Clinical biochemistry 2019; (69()):30-35 doi:10.1016/j.clinbiochem.2019.05.012.

    PMID: 31145902
  4. 4

    Compound heterozygosity of a novel exon 3 frameshift (p.R357P fs*24) mutation and Y486D mutation in exon 5 of the UGT1A1 gene in a Thai infant with Crigler-Najjar syndrome type 2.

    Tesapirat L, Nilyanimit P, Wanlapakorn N, Poovorawan Y

    Genetics and molecular research : GMR 2015; (14(2)):3293-9 doi:10.4238/2015.April.13.8.

    PMID: 25966095
  5. 5

    [Analysis of mutation site characteristics of Gilbert syndrome and Crigler--Najjar syndrome in relation to uridine diphosphate glucuronosyltransferase A1 gene].

    Liang C, Luo L, Bai J, et al.

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2020; (28(5)):428-433 doi:10.3760/cma.j.cn501113-20200217-00051.

    PMID: 32536060
  6. 6

    Crigler-Najjar Syndrome Type II Diagnosed in a Patient with Jaundice Since Birth.

    Liaqat A, Shahid A, Attiq H, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2018; (28(10)):806-808 doi:3028.

    PMID: 30266131
  7. 7

    Two Different UGT1A1 Mutations causing Crigler-Najjar Syndrome types I and II in an Iranian Family.

    Maruo Y, Behnam M, Ikushiro S, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2015; (24(4)):523-6 doi:10.15403/jgld.2014.1121.244.ugt.

    PMID: 26697581
  8. 8

    p.Cys223Tyr mutation causing Crigler-Najjar syndrome type II.

    Xiong QF, Zhou H, Yang YF

    JGH open : an open access journal of gastroenterology and hepatology 2020; (4(5)):1009-1011 doi:10.1002/jgh3.12355.

    PMID: 33102778
  9. 9

    A rare case of Crigler-Najjar syndrome type 2: A case report and literature review.

    Rijal D, Rijal P, Bohare SM, et al.

    Clinical case reports 2023; (11(11)):e8176 doi:10.1002/ccr3.8176.

    PMID: 38028034
  10. 10

    From Childhood Icterus to Adolescent Gallstones: Clinically Diagnosed Crigler-Najjar Syndrome Type II.

    Goswami DK, Goswami B, Shaikh S, et al.

    Clinical case reports 2026; (14(2)):e72080 doi:10.1002/ccr3.72080.

    PMID: 41727742
  11. 11

    Disruption of HNF1α binding site causes inherited severe unconjugated hyperbilirubinemia.

    van Dijk R, Mayayo-Peralta I, Aronson SJ, et al.

    Journal of hepatology 2015; (63(6)):1525-9.

    PMID: 26220753
  12. 12

    A novel UGT1A1 gene mutation causing severe unconjugated hyperbilirubinemia: a case report.

    Shi X, Aronson S, Khan AS, Bosma PJ

    BMC pediatrics 2019; (19(1)):173 doi:10.1186/s12887-019-1555-y.

    PMID: 31142299
  13. 13

    Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1.

    Apgar JF, Tang JP, Singh P, et al.

    CPT: pharmacometrics & systems pharmacology 2018; (7(6)):404-412 doi:10.1002/psp4.12301.

    PMID: 29637732
  14. 14

    Spectrum of UGT1A1 Variations in Chinese Patients with Crigler-Najjar Syndrome Type II.

    Li L, Deng G, Tang Y, Mao Q

    PloS one 2015; (10(5)):e0126263 doi:10.1371/journal.pone.0126263.

    PMID: 25993113
  15. 15

    [Study on spectrum of UGT1A1 mutations in connection with inherited non-hemolytic unconjugated hyperbilirubinemia].

    Xiong QF, Zhong YD, Feng XN, et al.

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2018; (26(12)):898-902 doi:10.3760/cma.j.issn.1007-3418.2018.12.005.

    PMID: 30669781
  16. 16

    Gunn Rats as a Surrogate Model for Evaluation of Hepatocyte Transplantation-Based Therapies of Crigler-Najjar Syndrome Type 1.

    Polgar Z, Li Y, Li Wang X, et al.

    Methods in molecular biology (Clifton, N.J.) 2017; (1506()):131-147 doi:10.1007/978-1-4939-6506-9_9.

    PMID: 27830550
  17. 17

    UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults.

    Bai J, Li L, Liu H, et al.

    Journal of clinical and translational hepatology 2021; (9(2)):180-186 doi:10.14218/JCTH.2020.00108.

    PMID: 34007799
  18. 18

    Novel UGT1A1 Gene Mutations in a Boy with Crigler-Najjar Syndrome Type II.

    Pérez-Solís D, Montes-Zapico B, Rodríguez-Dehli AC, et al.

    Journal of pediatric genetics 2021; (10(4)):323-325 doi:10.1055/s-0040-1714361.

    PMID: 34849280
  19. 19

    Management of Crigler-Najjar syndrome.

    Tcaciuc E, Podurean M, Tcaciuc A

    Medicine and pharmacy reports 2021; (94(Suppl No 1)):S64-S67 doi:10.15386/mpr-2234.

    PMID: 34527915
  20. 20

    A Novel Pathogenic UGT1A1 Variant in a Sudanese Child with Type 1 Crigler-Najjar Syndrome.

    Elfar W, Järvinen E, Ji W, et al.

    Drug metabolism and disposition: the biological fate of chemicals 2019; (47(1)):45-48 doi:10.1124/dmd.118.084368.

    PMID: 30385458
  21. 21

    Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.

    Strauss KA, Ahlfors CE, Soltys K, et al.

    Hepatology (Baltimore, Md.) 2020; (71(6)):1923-1939 doi:10.1002/hep.30959.

    PMID: 31553814

This page explains Crigler-Najjar Syndrome subtypes for educational purposes only. Always consult your child's pediatrician, hepatologist, or geneticist for an accurate diagnosis and treatment plan.

Get notified when new evidence is published on Crigler-Najjar syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.